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ABSTRACT
This review aimed to discuss the importance of the comprehensive treatment 
of depression among older adults in Brazil. The abuse of selective serotonin 
reuptake inhibitors, including fluoxetine hydrochloride, as antidepressants has 
been considered a serious public health problem, particularly among older 
adults. Despite the consensus on the need for a comprehensive treatment of 
depression in this population, Brazil is still unprepared. The interface between 
pharmacotherapy and psychotherapy is limited due to the lack of healthcare 
services, specialized professionals, and effective healthcare planning. 
Fluoxetine has been used among older adults as an all-purpose drug for the 
treatment of depressive disorders because of psychosocial adversities, lack 
of social support, and limited access to adequate healthcare services for the 
treatment of this disorder. Preparing health professionals is a sine qua non 
for the reversal of the age pyramid, but this is not happening yet.
DESCRIPTORS: Aged. Depression, therapy. Medicalization. 
Fluoxetine, therapeutic use. Comprehensive Health Care.
Comments DOI:10.1590/S0034-8910.2015049005835
Gabriela Arantes WagnerI,II,III
2 Treatment of depression in older adults Wagner GA
Human aging is a natural process characterized by 
increasing vulnerability. Brazilian public policies have 
been receiving support from research groups to gain a 
better understanding of this problem.8,9 This support 
involves evaluating strategies that are essential for the 
improvement and consolidation of healthcare programs 
and even for the reporting of possible damage caused 
by certain technologies in health. The demographic and 
epidemiological transition imposes challenges to public 
health, aging, and the training of primary healthcare 
professionals for the diagnosis, maintenance, and treat-
ment of older adults with depression.
This article discusses the importance of comprehen-
sive treatment for depression among older adults in 
Brazil other than using pharmacotherapy, which mainly 
involves selective serotonin reuptake inhibitors (SSRI). 
It focuses on the importance of professional training 
and improvement of healthcare policies for this specific 
population group.
DEPRESSION IN OLDER ADULTS
As with other mental disorders, depression in older adults 
is due to biological, psychological, and social factors. 
The depressive symptoms in this age group are more 
common in women or when the symptoms are associ-
ated with Alzheimer’s disease and constitute predictors 
for the development of dementia.1 The disease usually 
manifests in individuals living with psychosocial adver-
sities, such as breaking of family ties, loss of social 
contacts, previous history of depression, stressful life 
events, widowhood, living in clinics or nursing homes, 
RESUMO
Esse comentário tem como objetivo discutir a importância da multidisciplinariedade 
do tratamento da depressão do idoso no Brasil. O abuso de prescrições de 
antidepressivos inibidores seletivos da receptação de serotonina, como o 
cloridrato de fluoxetina, já tem sido apontado como grave problema de saúde 
pública, especialmente entre idosos. Embora seja consenso a necessidade de 
multidisciplinariedade no tratamento da depressão nessa população, o Brasil 
ainda encontra-se despreparado. A interface entre farmacoterapia e psicoterapia 
encontra-se prejudicada por falta de serviços, de profissionais especializados e 
de planejamento assistencial efetivo. A fluoxetina tornou-se uma “muleta” para a 
cura de males causados pelas adversidades psicossociais, falta de suporte social 
e de acesso a serviços de saúde adequados para o tratamento desse transtorno 
em idosos. É condição sine qua non haver preparo para a inversão das pirâmides 
etárias, o que parece não acontecer atualmente.
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INTRODUCTION
low-income status, and lack of social support. Moreover, 
analysis of the incidence of symptoms in older age groups 
indicates that morbidity and frailty are the most impor-
tant factors in the etiology of this disease.1,11
The treatment of depression in older adults should 
consider all the factors involved in the disorder, 
i.e., the treatment should involve a combination 
of psychotherapy and pharmacotherapy. There is a 
consensus that neither of these therapies alone is effec-
tive for the remission of depression in older adults.13
MEDICAL THERAPY
With regard to pharmacotherapy, the use of antidepres-
sants among older adults has evolved over the years.13 
However, since the introduction of SSRI to the market 
in the 1980s, a preference has developed for them. 
Although they are metabolized by cytochrome P450 
isoenzymes (which increase the possibility of drug 
interactions with other drugs metabolized by the same 
route), they have a lower risk of adverse reactions 
compared with the other antidepressants previously 
available in primary care health services, including 
tricyclic drugs and monoamine oxidase inhibitors.4
In addition, because of variations in dose, duration of 
treatment, and the low incidence of adverse effects, 
SSRI are the drug of choice for the treatment of patients 
with depression. The most important active ingredients 
in these drugs are sertraline hydrochloride, escitalo-
pram, and venlafaxine; however, fluoxetine hydrochlo-
ride is the most commonly used at present.13
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In Brazil, the National List of Essential Medicinesa lists 
only fluoxetine hydrochloride within this class of anti-
depressants. From 2005 to 2009, the sales of antide-
pressants increased by 44.8% from R$647.7 million to 
R$976.9 million.b With regard to fluoxetine hydrochlo-
ride, in 2009, a defined daily dose (DDD) of 2.62 mg 
per 1,000 inhabitants per day was established in Brazil. 
Santa Catarina, Rio Grande do Sul, Federal District, 
Paraná, and Goiásb were the five states with the largest 
per capita consumers.
PHARMACOTHERAPY
The introduction and maintenance of pharmacotherapy 
among older adults have increased. The number of fluox-
etine prescriptions is increasing annually in this popula-
tion group, even among the very old.10 In addition, the use 
of fluoxetine is increasingly prevalent among older adults 
with characteristics common to those who abuse benzo-
diazepines, i.e., women who report anxiety complaints, 
loneliness, and lack of family or social support. As previ-
ously observed for benzodiazepines, pressure from the 
pharmaceutical industry, associated with the low cost of 
the drug, positive reinforcement of chronic users, wrong 
indication, and a lack of academic preparation of profes-
sionals who interact with the patients, result in excessive 
drug prescription and dispensing.12
This is the context into which “another drug in the 
polypharmacy of older adults”7 is being incorporated. 
The main indications for treatment with SSRI in older 
patients should be reviewed, as was done with the use 
of benzodiazepines.12 The current discussions focus on 
who prescribes, how it is prescribed, for what reasons, 
and how it is dispensed. Moreover, even in developed 
countries, it is known that the type of treatment for 
depression among older adults depends significantly 
on socioeconomic factors. In addition, the conditions 
offered by the healthcare systems are obsolete.6
General practitioners claim that older patients do not need 
to seek specialized care in mental health centers because 
these professionals are confident in their diagnosis and in 
the pharmacotherapy strategy adopted, and they are the 
ones who prescribe most psychotropic drugs. For this 
reason, with the dissemination of new and safer treatments, 
the number of diagnoses of depression has increased signif-
icantly among older adults, who are rarely evaluated from 
the perspective of geriatric diagnostic criteria. Furthermore, 
these patients are diagnosed with disorders other than 
depressive disorders during treatment with SSRI.6
It is not only doctors who should be held responsible for 
the increased use of these drugs. Pharmacists play an 
essential role in the interaction with this population group, 
because they are responsible for dispensing the drugs. 
Polypharmacy is complex and involves the whole produc-
tion chain of the medication – production, regulation, 
availability in the health care systems, and dispensing.5 
With regard to the latter, most Brazilian pharmacists who 
work as in-charge pharmacists in drugstores or primary 
healthcare services do not understand their role as health 
professionals. With the exception of those who specialize 
in clinical pharmacy and those who work in geriat-
rics, pharmaceutical care for older adults is inadequate. 
Training these professionals to help them understand the 
demographic transition and the importance of observation 
and notification of drug overuse or increased prescription 
occurs in very few academic curricula.
SERVICES, POLICIES, AND HEALTH PROMOTION
Although the psychosocial support centers (PSC) have 
been created to organize municipal healthcare services 
for individuals with severe and persistent mental 
disorders, geriatric care is limited in the healthcare 
network, not to mention the inequity in the access to 
these services. As recommended by the World Health 
Organization regarding the incorporation of the deter-
minants of health in the organization of effective 
healthcare networks,c the innovation of mental health 
care services for this population group is essential.
In fact, the guidelines of the National Health Policy for 
Older Adultsd include prevention, recovery, and reha-
bilitation of older patients with mental disorders to 
assure that they experience aging free of disabilities.e 
However, effective healthcare planning requires diag-
noses that involve appropriate clinical assessment, 
which can only be done by geriatricians and healthcare 
professionals with problem-solving abilities related to 
the treatment of several pathologies in older adults and 
not simply by prescribing medications.
Individuals with chronic conditions are more likely to 
develop depressive symptoms and are less able to control 
various aspects of their lives, which directly affects their 
subjective perception in evaluating and coping with 
stressful conditions.15 Therefore, the sociocultural factors 
that negatively affect the quality of life in this popula-
tion need to be minimized in order to contribute to the 
promotion of health. In fact, these factors cannot be 
addressed simply with the use of SSRI, benzodiazepines, 
a Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e Insumos 
Estratégicos. Relação nacional de medicamentos essenciais: Rename. 7. ed. Brasília (DF); 2010.
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(DF); 2009.
c Organização Mundial da Saúde. A Saúde e o Envelhecimento. In: 26a Conferência Sanitária Pan-Americana. Washington (DC); 2002.
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or any other drugs that target the central nervous system, 
because our society demands the incorporation of older 
adults in their full potential.
CONCLUSION
This wide range of biological and psychosocial factors 
associated with depressive disorders among older 
adults requires the implementation of public policies, 
including those related to healthcare, in all their spheres 
of complexity; and this strategy should contemplate 
the comprehensive nature of the disease3 not only to 
decrease the stigma caused by depression but also to 
improve the quality of life in aging and treatment effi-
cacy and effectiveness.2 In the United States, approxi-
mately 10.0% of older patients suffering from depres-
sion attempt suicide each year.13 In Brazil, an explor-
atory analysis conducted between 2005 and 2007 in 
Brazilian cities that recorded deaths due to suicide 
among individuals around 60 years of age indicated 
that these deaths were positively correlated with mood 
disorders.14 In this context, it is necessary to recognize 
the many ramifications of depression among older 
patents for proper treatment, which should not be based 
on pharmacotherapy alone.
The abuse of SSRI by older adults reflects the lack of 
preparation of healthcare professionals for the treat-
ment of depression in this group. In addition, the use 
of these medications for other purposes other than 
their main indication makes fluoxetine hydrochloride 
an objectionable all-purpose drug to treat disorders 
associated with psychosocial adversity, lack of social 
support, and limited access to healthcare services neces-
sary for the treatment of mental disorders. Therefore, 
preparing healthcare professionals for the reversal of the 
age pyramid is essential, but this is not happening yet.
1. Alexopoulos GS. Depression in elderly. 
Lancet. 2005;365(9475):1961-70. 
DOI:10.1016/S0140-6736(05)67091-2
2. Büchtemann D, Luppa M, Bramesfeld A, Riedel-Heller 
S. Incidence of late life depression: a systematic 
review. J Affect Disord. 2012;142(1-3):172-9. 
DOI:10.1016/j.jad.2012.05.010
3. Camacho ACLF, Coelho MJ. Políticas públicas 
para a saúde do idoso: revisão sistemática. 
Rev Bras Enferm. 2010;63(2):279-84. 
DOI:10.1590/S0034-71672010000200017
4. Carlini EA, Noto AR, Nappo SA, Sanchez ZM, Franco 
VLS, Silva LCF, et al. Fluoxetina: indícios de uso 
inadequado. J Bras Psiquiatr. 2009;58(2):97-100. 
DOI:10.1590/S0047-20852009000200005
5. Carvalho MFC, Romano-Lieber NS, Bergsten-Mendes 
G, Secoli SR, Ribeiro E, Lebrão ML, et al. Polifarmácia 
entre idosos do Município de São Paulo - Estudo 
SABE. Rev Bras Epidemiol. 2012;15(4):817-27. 
DOI:10.1590/S1415-790X2012000400013
6. Crystal S, Sambamoorthi U, Walkup JT, Akincigil. 
Diagnosis and treatment of depression in the elderly 
medicare population: predictors, disparities, and 
trends. J Am Geriatr Soc. 2003;51(12):1718-28. 
DOI:10.1046/j.1532-5415.2003.51555.x
7. Hilmer SN, Gnjidic D. The effects of polypharmacy in 
older adults. Clin Pharmacol Ther. 2009;85(1):86-8. 
DOI:10.1038/clpt.2008.224
8. Lebrão ML, Laurenti R. Saúde, bem-estar e 
envelhecimento: o estudo SABE no município de 
São Paulo. Rev Bras Epidemiol. 2005;8(2):127-41. 
DOI:10.1590/S1415-790X2005000200005
9. Lima-Costa MF, Uchôa E, Guerra HL, Firmo JOA, Vidigal 
PG, Barreto SM. The Bambuí Health and Ageing Study 
(BHAS): methodological approach and preliminary 
results of a population-based cohort study of the elderly 
in Brazil. Rev Saude Publica. 2000;34(2):126-35. 
DOI:10.1590/S0034-89102000000200005
10. Loyola Filho A, Castro-Costa E, Firmo JOA, Peixoto 
SV. Tendências no uso de antidepressivos entre idosos 
mais velhos: Projeto Bambuí. Rev Saude Publica. 
2014;48(6):857-65.
11. Luppa M, Sikorski C, Luck T, Ehreke L, Konnopka A, 
Wiese B, et al. Age-and gender-specific prevalence 
of depression in latest-life – Systematic review and 
meta-analysis. J Affect Disord. 2012;136(3):212-21. 
DOI:10.1016/j.jad.2010.11.033
12. Madhusoodanan S, Bogunovic OJ. Safety of 
benzodiazepines in the geriatric population. 
Expert Opin Drug Saf. 2004;3(5):485-93. 
DOI:10.1517/14740338.3.5.485
13. Mukai Y, Tamp RR. Treatment of depression in the 
elderly: a review of the recent literature on the efficacy 
of single-versus dual-action antidepressants. Clin Ther. 
2009;31(5):945-58. DOI:10.1016/j.clinthera.2009.05.016
14. Pinto LW, Silva CMFP, Pires TO, Assis SG. Fatores 
associados com a mortalidade por suicídio de 
idosos nos municípios brasileiros no período de 
2005-2007. Cienc Saude Coletiva. 2012;17(8):2003-9. 
DOI:10.1590/S1413-81232012000800011
15. Rabelo DF, Neri AL. Recursos psicológicos e 
ajustamento pessoal frente à incapacidade funcional 
na velhice. Psicol Estud. 2005;10(3):403-12. 
DOI:10.1590/S1413-73722005000300008
16. Veras R. Envelhecimento populacional 
contemporâneo: demandas, desafios e inovações. 
Rev Saude Publica. 2009;43(3):548-54. 
DOI:10.1590/S0034-89102009005000025
REFERENCES
The authors declare no conflict of interest.
